药物对比
Saxagliptin vs Troglitazone
比较Saxagliptin（现行DPP-4抑制剂）与Troglitazone（已撤市噻唑烷二酮类）治疗糖尿病。安全性差异，尤其是肝毒性，以及目前的可获得性。
此页面暂无可用的对比维度。
临床背景
When evaluating current DPP-4 inhibitors against historically used thiazolidinediones for type 2 diabetes management.
结论
Saxagliptin is the currently available and safer choice over the withdrawn Troglitazone.
全部药物对比